

The 13th Annual Meeting of Asian Organization for Crohn's & Colitis (AOCC2025)

Luncheon Seminar 4

Cutting-edges of Ulcerative Colitis Treatment: focusing on Introduction of Oral Advanced Therapy

Date 2025. 7.12 SAT 12:00-12:50

Venue

Room1

Makuhari Messe International Conference Hall 2F Convention Hall A 2-1,Nakase,Mihama-ku,Chiba City, Chiba,261-8550,Japan



Toshifumi Hibi, MD

Special Adviser, IBD Center Kitasato University Kitasato Institute Hospital



Geert D'Haens, MD, PhD

Professor of Gastroenterology, Chair of the department of Gastroenterology and Hepatology, Amsterdam University Medical Centers



Motohiro Esaki, MD, PhD

Professor, Division of Gastroenterology,
Department of Internal Medicine, Faculty of Medicine, Saga University

*Participants will be provided with boxed lunches (limited quantity)

Co-sponsored: The 13th Annual Meeting of Asian organization for Crohn's & Colitis (AOCC2025) \ Pfizer Japan Inc.



Etrasimod is an oral, once daily, selective sphingosine 1-phosphate1,4,5 (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis*

*INDICATIONS in Japan: Treatment of moderate to severe ulcerative colitis (only in patients who have had an inadequate response to existing therapies



Pfizer Japan Inc. Exhibition Booth Information

Event Period | July 10-12, 2025

Exhibit Details at the Booth

At the Pfizer booth, we are pleased to present our pharmaceutical formulations, along with a selection of beverages inspired by countries where VEL has received approval. We warmly invite you to visit us.



Booth location

Makuhari Messe International Conference Hall 2F

